Table 6 Detection of PCs as potential biomarkers for the diagnosis of early-stage NSCLC.

From: Simultaneous quantification of serum monounsaturated and polyunsaturated phosphatidylcholines as potential biomarkers for diagnosing non-small cell lung cancer

No.

Biomarker

p value

q value

Fold-change

AUC (95% CI)

Sensitivity (%)

Specificity (%)

Trend (Cancer)

1

PC(17:2/2:0)

1.86E-05

6.38E-04

0.51

0.183 (0.078–0.288)

66.7

86.7

down

2

PC(18:4/3:0)

1.18E-03

6.07E-03

0.59

0.233 (0.110–0.356)

66.7

83.3

down

3

PC(15:0/18:2)

7.15E-03

1.92E-02

0.81

0.283 (0.147–0.420)

56.7

90.0

down

4

PC(16:0/18:3)

1.13E-03

2.27E-02

0.63

0.218 (0.101–0.335)

83.8

70.0

down

5

PC(17:0/18:2)

5.72E-04

4.36E-03

0.79

0.250 (0.125–0.375)

70.0

73.3

down

6

PC(18:2/18:2)

1.05E-03

5.81E-03

0.69

0.254 (0.128–0.381)

53.3

93.3

down

7

PC(16:0/20:3)

1.42E-03

6.48E-03

0.65

0.252 (0.126–0.378)

60.0

90.0

down

8

PC(15:0/22:6)

4.00E-04

3.63E-03

0.71

0.243 (0.121–0.365)

53.5

90.0

down

9

PC(24:4/17:2)

3.78E-03

1.30E-02

0.78

0.273 (0.139–0.407)

70.0

80.0

down

10

PC(15:0/18:1)

8.26E-03

2.07E-02

1.64

0.717 (0.586–0.848)

60.0

80.0

up

11

PC(18:0/16:0)

5.27E-03

1.62E-02

1.34

0.763 (0.641–0.885)

73.3

76.7

up

12

PC(18:0/20:1)

1.96E-03

3.28E-02

1.53

0.691 (0.556–0.826)

66.7

70.0

up

 

Panel a

—

 

—

0.897 (0.818–0.975)

90.0

76.7

 
 

Panel b

—

 

—

0.811 (0.703–0.919)

76.7

70.0

 
 

Panel c

—

 

—

1.000 (1.000–1.000)

100

100

 
  1. Panel (a): combination of down-regulated PCs; Panel b: combination of up-regulated PCs.
  2. Panel (c): combination of 12 altered PCs.